Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: Pathophysiology and management

Seminars in Liver Disease

Volumn 16, Issue 4, 1996, Pages 379-387

  Ellis, Antony ^a   Wendon, Julia ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Cerebral edema; Hemodynamics; Liver failure; Renal

Indexed keywords

ACETYLCYSTEINE; PROSTACYCLIN;

ASSISTED VENTILATION; BRAIN BLOOD FLOW; BRAIN EDEMA; HEART OUTPUT; HUMAN; HYPOTENSION; KIDNEY FAILURE; LIVER FAILURE; LIVER METABOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMIC VASCULAR RESISTANCE; TISSUE OXYGENATION; TREATMENT PLANNING;

BLOOD CIRCULATION; BRAIN EDEMA; CARDIOVASCULAR DISEASES; CEREBROVASCULAR CIRCULATION; HEMODYNAMIC PROCESSES; HUMANS; HYPOTENSION; KIDNEY FAILURE; LIVER FAILURE, ACUTE;

EID: 0030480412     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007251     Document Type: Article

References (63)

1. Bihari D, Gimson AE, Lindridge J, Williams R: Lactic acidosis in fulminant hepatic failure. Some aspects of pathogenesis and prognosis. J Hepatol 1:405-16, 1985.
2. O'Grady JG, Gimson AE, O'Brien CJ, et al: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94:1186-92, 1988.
3. Muto Y, Nouri-Aria K, Meager A, et al: Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet ii:72-4, 1988.
4. Sheron N. Goka J, Wendon J, et al: Highly elevated levels of plasma cytokines in fulminant hepatic failure: correlations with multiorgan failure and death. Hepatology 12:939, 1990.
5. Shiratori Y, Moriwaki H, Kawashima Y: Elevated interleukin-6 levels in sera of patients with fulminant hepatic failure. Gastroenterol Jpn 26:233, 1991.
6. Evans PJ, Evans RW, Bomford A, et al: Metal ions catalytic for free radical reactions in the plasma of patients with fulminant hepatic failure. Free Rad Res 20:139-44, 1994.
7. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-6, 1987.
8. Ignarro LJ, Buga GM, Wood KS, et al: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84:9265-9, 1987.
9. Hibbs JR, Taintor RR, Vavrin Z, Rachlim EM: Nitric oxide: A cytotoxic activated macrophage effector molecule. Biophy Res Commun 157:87-94, 1988.
10. Stuehr DJ, Gross SS, Sakuma I, et al: Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical activity of nitric oxide. J Exp Med 169:1011-20, 1989.
11. Liew FY, Millott S, Parkinson C, et al: Macrophage killing of Leishmania parasite in-vivo is mediated by nitric oxide from L-arginine. J Immunol 144:4794-7, 1990.
12. Chase R, Davies M, Trewby P, et al: Plasma amino acid profiles in patients with fulminant hepatic failure treated by repeated polyacrylonitrile membrane haemodialysis. Gastroenterology 75:1033-40, 1978.
13. Harrison P, O'Grady J, Alexander G, Williams R: Serial prothrombin times: a prognostic indicator in paracetamol-induced fulminant hepatic failure. Br Med J 301:964-6, 1990.
14. Keays R, Harrison PM, Wendon JA, et al: Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. Br Med J 303:1026-9, 1991.
15. Harrison PM, Wendon JA, Gimson AES, et al: Improvement by acetylcysteine of haemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 324:1852-8, 1991.
16. Harrison P, Wendon J, Williams R: Evidence of increased guanylate cyclase activation in fulminant hepatic failure. Hepatology 23:1067-72, 1996.
17. Haupt MT, Gilbert EM, Carlson RW: Fluid loading increases oxygen consumption in septic patients with lactic acidosis. Am Rev Respir Dis 131:912-16, 1985.
18. Bihari DJ, Gimson AE, Williams R: Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. Sem Liver Dis 6:119-28, 1986.
19. Imawari M, Hughes RJD, Gove CD, Williams R: Fibronectin and Kuppfer cell function in fulminant hepatic failure. Dig Dis Sci 30:1028-33, 1985.
20. Wendon J, Harrison P, Keays R, el al: Effects of vasopressor agents and epoprostenol on systemic hemodynamics on oxygen transport variables in patients with fulminant hepatic failure. Hepatology 15:1067-71, 1992.
21. Slotman G, Machiedo G, Novak R, Bush B: The hemodynamic effect of profound hypercapnia on acute hypoxic respiratory failure. Circ Shock 11:187-94, 1983.
22. Utsunomiya T, Krauz M, Valeria C, et al: The treatment of pulmonary embolus with epoprostenol- Surgery 88:25-8, 1980.
23. Bihari DJ, Tinker J: The therapeutic value of vasodilator prostaglandins in multiple organ failure associated with sepsis. Int Care Med 15:2-7, 1988.
24. Kondrup JAT, Vilstrup H, Tygstrup N: High volume plasma exchange in fulminant hepatic failure. Int J Art Org 11:669-76, 1992.
25. Wyke RJ, Rajkovic LA, Eddleston AWLF, Williams R: Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut 21:643-9, 1980.
26. Ware AJ, D'Agostimo AN, Coombes B: Cerebral edema: A major complication of massive hepatic necrosis. Gastroenterology 61:877-84, 1971.
27. Blei A: Cerebral edema and intracranial hypertension in acute liver failure: distinct aspects of the same problem. Hepatology 13:376-9, 199l
28. Ede RJ, Williams R: Hepatic encephalopathy and cerebral edema. Sem Liver Dis 6:107-18, 1986.
29. Trewby PN, Hanid MA, Mackenzie RL, et al: Effects of cerebral edema and arterial hypotension on cerebral blood flow in an animal model of hepatic failure. Gut 19:999-1005, 1978.
30. Shah V, Webster S, Gottstein J, Blei AT: Reduction in cerebral perfusion precedes rise of intracranial pressure in rats with ischaemic fulminant liver failure. Hepatology 17:1117-21, 1993.
31. Almdal T. Schroeder T, Ranek L: Cerebral blood flow and liver function in patients with encephalopathy due to acute and chronic liver diseases. Scand J Gastroenterol 24:299-303, 1989.
32. 2 in patients with hepatic or septic encephalopathy. Resuscitation 19:125-34, 1990.
33. Larsen FS, Hansen BA, Jorgensen LG, et al: Cerebral blood flow velocity during high volume plasmapheresis in fulminant hepatic failure. Int J Art Org 17:353-61, 1994.
34. Kramer D, Aggarwal M, Darby J, et al: Management options in fulminant hepatic failure. Transplant Proceed 23:1895-8, 1991.
35. Aggarwal S, Kramer D, Yonas H, et al: Cerebral haemodynamic and metabolic changes in fulminant hepatic failure: A retrospective study. Hepatol 19:80-87, 1994.
36. Wendon J, Harrison P, Keays R, Williams R: Cerebral blood flow and metabolism in fulminant hepatic failure, Hepatology 19:1407-13, 1994.
37. +ATPase activity in rats with galactosamine-induced hepatic failure: relationship to encephalopathy and cerebral oedema. Clin Sci 72:365-71, 1987.
38. +-ATPase by hemoperfusion in fulminant hepatic failure. Artif Organs 8:174-8, 1984.
39. Jafar JJ, Johns LM, Mullan SF: The effect of mannitol on cerebral blood flow. J Neurosurg 64:754-9, 1986.
40. Harrison PM, Keays R, Bray GP, et al: Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1:1572-3, 1990.
41. Makin AJ, Wendon J, Williams R: A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 109:1907-16, 1995.
42. Ede RJ, Gimson AE, Bihari D, Williams R: Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 2:43-51, 1986.
43. Forbes A, Alexander GJ, O'Grady JG, et al: Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology 10:306-10, 1989.
44. Blei A, Olafsson S, Webster S, Levy R: Complications of intracerebral pressure monitoring in fulminant hepatic failure, Lancet 341:157-8, 1993.
45. Lidofsky SD, Bass MM, Prager MC, et al: Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 16:1-7, 1992.
46. Keays RT, Alexander GJ, Williams R: The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol 18:205-9, 1993.
47. Ellis AJ. Wendon J, Williams R: Efficacy and safety of intracranial pressure monitoring in fulminant hepatic failure. J Hepatol 21:S51, 1994.
48. Donovan JP, Shaw JR, Langnas AN, Sorrell MF: Brain water and acute liver failure: the emerging role of intracranial pressure monitoring. Hepatology 16:267-8, 1992.
49. Davies MH, Mutimer D, Lowes J, et al: Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet 343:1329-30, 1994.
50. Munoz S, Robinson M, Northup B, et al: Elevated intracranial pressure and computed tomography of the brain in fulminant hepatocellular failure. Hepatology 13(2):209-12, 1991.
51. Ringe B, Pichlmayr R, Lubbe N, et al: Total hepatectomy as a temporary approach to acute hepatic or primary graft failure. Trans Proc XX:552-7, 1988.
52. Rozga J, Podesta L, LePage E, et al: Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure. Lancet 342:898-9, 1993.
53. Ring-Larsen H, Palazzo U. Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis. Gut 22:585-91, 1981.
54. Wilkinson SP, Blendis IK, Williams R: Frequency and type of renal and electrolyte disorders in fulminant hepatic failure. Br Med J i: 186-9, 1974.
55. Moore K, Taylor G, Ward P, Williams R: Aetiology and management of renal failure in acute liver failure. In Williams R (ed): Acute Liver Failure: Improved understanding and better therapy. RD Hughes, 1991, pp 47-53.
56. Wilkinson SP, Arroyo V, Gazzard BG, et ai: Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet i:521-4, 1974.
57. 2 and prostacyclin in decompen-sated liver disease and hepatorenal syndrome. Gastroenterology 100:1069-77, 1991.
58. Huber M, Kastner S, Scholmerich J, et al: Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome. Eur J Clin Invest 39:53-60, 1989.
59. Govindarajan S, Nast CC, Smith WL, et al: Immunohistochemical distribution of renal endoperoxide synthase and prostacyclin synthase: Diminished endoperoxidase synthase in the hepatorenal syndrome. 7:654-9, 1987.
60. Moore K, Wendon J, Frazer M, et al: Plasma endothelin im-munoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327:1774-8, 1992.
61. Thompson BT, Cockrill BA: Renal-dose dopamine: a siren song? Lancet 344:7-8, 1994.
62. Davenport A, Will EJ, Davison AM, et al: Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy. Nephron 53:142-6, 1989.
63. Langley PG, Hughes RD, Williams R: Platelet adhesiveness to glass beads in liver disease. Acta Haemat 67:124-7, 1982.